Continuous Manufacturing is Here to Stay (PDA/FDA Joint Regulatory Conference 2023)
Kelley Burridge, PhD, Product Quality Team Leader, OBP, OPQ, CDER, U.S. FDA, discusses the importance of continuous manufacturing for the future.
In part of the session "Continuous Manufacturing and Publication of ICH Q13" at the PDA/FDA Joint Regulatory Conference, Kelley Burridge, PhD, Product Quality Team Leader, OBP, OPQ, CDER, U.S. FDA, discusses the importance of continuous manufacturing for the future.
Burridge: Continuous manufacturing is here. An evolution of pharmaceutical quality over the last several decades started with adoption of risk based approaches, as this analytical Technology and Quality by design have set the stage for adoption of continuous manufacturing. What's needed for approval of continuous manufacturing packages is the same as what's needed for batch processes. A demonstration of pharmaceutical quality demonstrate that you understand your product and your process and that you have the capability to operate a well controlled process, consistent with manufacturer's quality guide.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
